Premium
Histone deacetylase inhibitors and periodontal bone loss
Author(s) -
Cantley M. D.,
Bartold P. M.,
Marino V.,
Fairlie D. P.,
Le G. T.,
Lucke A. J.,
Haynes D. R.
Publication year - 2011
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/j.1600-0765.2011.01392.x
Subject(s) - osteoclast , porphyromonas gingivalis , periodontitis , histone deacetylase , chemistry , in vivo , bone resorption , inflammasome , histone deacetylase inhibitor , cancer research , inflammation , medicine , endocrinology , in vitro , histone , biology , biochemistry , microbiology and biotechnology , gene
Cantley MD, Bartold PM, Marino V, Fairlie DP, Le GT, Lucke AJ, Haynes DR. Histone deacetylase inhibitors and periodontal bone loss. J Periodont Res 2011; 46: 697–703. © 2011 John Wiley & Sons A/S Background and Objective: Bone loss caused by enhanced osteoclast activity is a significant feature of periodontitis. Histone deacetylase inhibitors (HDACi) can suppress osteoclast‐mediated bone loss in vitro and in vivo . This study investigated whether HDACi can suppress bone loss in experimental periodontitis. Material and methods: Experimental periodontitis was induced in mice by oral inoculation with Porphyromonas gingivalis bacteria. Mice were treated orally with olive oil alone, with olive oil and a novel compound – 1179.4b – which targets both Class I and Class II histone deacetylases (HDACs) or with olive oil and MS‐275, which targets Class I HDACs. Micro‐computed tomography scans of live mice, stereo imaging and histological analyses were used to detect changes in bone. Results: In the absence of treatment there was a 13.2% increase in bone volume in controls compared with a 7.4% decrease in P. gingivalis ‐inoculated mice. 1179.4b significantly reduced bone loss, with a 3.4% increase in bone volume ( p < 0.01). MS‐275 did not have a significant effect on P. gingivalis ‐induced bone loss. Histological analysis revealed that 1179.4b reduced bone loss despite having no effect on inflammation. Conclusion: HDACi were found to effectively suppress bone loss in the mouse model of periodontitis. 1179.4b – the inhibitor of Class I and Class II HDACs – was more effective at suppressing bone loss than MS‐275, which targets Class I HDACs only. These compounds may therefore have the potential to be used for the management of periodontitis.